帕罗伐汀|T4538|TargetMol

palovarotene
410528-02-8

￥279 1mg 起订

￥619 5mg 起订

￥987 10mg 起订

上海更新日期：2025-11-17

TargetMol中国（陶术生物）

VIP4年

联系人：邵小姐

手机：4008200310 拨打

邮箱：marketing@tsbiochem.com

产品详情:

中文名称：: 帕罗伐汀

英文名称：: palovarotene

CAS号：: 410528-02-8

品牌：: TargetMol

产地：: 美国

保存条件：: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

产品类别：: 抑制剂

货号：: T4538

Product Introduction

Bioactivity

名称	palovarotene
描述	Palovarotene (Ro 3300074) is an agonist of nuclear retinoic acid receptor γ (RAR-γ).
体内活性	Palovarotene inhibits post-traumatic chondrogenesis and osteogenesis and mitigated trauma-induced ectopic bone formation. Palovarotene inhibits subcutaneous and intramuscular heterotopic ossification (HO) in mice. Palovarotene (1 mg/kg/day ) is given orally for 14 days starting on a postoperative day (POD) 1 or POD-5, and HO amount wound dehiscence and related processes are monitored for up to 84 days post-injury. Compared to vehicle-control animals, Palovarotene significantly decreases HO by 50 to 60% regardless of when the treatment started and if the infection is present[1]. Starting from day 1 of injury, half of the Acvr1cR206H/+ mice are treated with Palovarotene by daily gavage for 14 days and the other half received a vehicle as control. Analysis by mCT and 3D image reconstruction at day 14 shows that large HO tissue masses have formed in the targeted leg of Acvr1cR206H/+ mutant mice receiving the vehicle, but HO formation is greatly diminished in Palovarotene-treated companions by more than 80% based on bone volume/total volume quantification[2].
存储条件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice/Shipping at ambient temperature.
溶解度	DMSO : 5.5 mg/mL (13.27 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1 mg/mL (2.41 mM), Sonication is recommended.
关键字	Ro-3300074 \| Ro3300074 \| RetinoidReceptor \| Retinoid X receptors \| Retinoid Receptor \| Retinoic acid receptors \| RARγ \| RAR/RXR \| R-667 \| R667 \| palovarotene \| Inhibitor \| inhibit \| Autophagy
相关产品	Naringin \| Guanidine hydrochloride \| Gefitinib \| Aceglutamide \| Alginic acid \| Cysteamine hydrochloride \| Hemin \| Hydroxychloroquine \| Stavudine \| Tamoxifen \| Paeonol \| Sodium 4-phenylbutyrate
相关库	经典已知活性库 \| 抗癌活性化合物库 \| 抗癌上市药物库 \| 已知活性化合物库 \| 靶向治疗药物库 \| 临床失败化合物库 \| EMA 上市药物库 \| 癌细胞分化化合物库 \| FDA 上市药物库 \| 药物功能重定位化合物库 \| 抗癌临床化合物库 \| 抗癌药物库

帕罗伐汀|||Ro 3300074|||R 667|TargetMol

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿，致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区，已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库，以及多种类型的生化试剂产品，包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等，此外，我们还建设有CADD（计算机辅助药物设计）研究中心、药理实验室、药化合成平台三大技术中心，全方位满足客户的定制需求。凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持，我们将有效帮助您缩短研发周期，取得更成功的结果。

成立日期	(13年)
注册资本	566.265100万人民币
员工人数	100-500人
年营业额	￥ 1亿以上
经营模式	贸易,工厂,试剂,定制,服务
主营行业	天然产物,生化试剂,分子生物学,分子砌块,生物技术服务